ANIX vs. IOBT, CLSD, GNLX, ETON, QTTB, YS, PRPH, ANVS, MIST, and BRNS
Should you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include IO Biotech (IOBT), Clearside Biomedical (CLSD), Genelux (GNLX), Eton Pharmaceuticals (ETON), Q32 Bio (QTTB), YS Biopharma (YS), ProPhase Labs (PRPH), Annovis Bio (ANVS), Milestone Pharmaceuticals (MIST), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical preparations" industry.
IO Biotech (NASDAQ:IOBT) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
Anixa Biosciences received 4 more outperform votes than IO Biotech when rated by MarketBeat users. However, 87.50% of users gave IO Biotech an outperform vote while only 64.29% of users gave Anixa Biosciences an outperform vote.
Anixa Biosciences has higher revenue and earnings than IO Biotech. Anixa Biosciences is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.
IO Biotech's return on equity of -44.09% beat Anixa Biosciences' return on equity.
54.8% of IO Biotech shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 2.3% of IO Biotech shares are held by insiders. Comparatively, 22.6% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, IO Biotech had 15 more articles in the media than Anixa Biosciences. MarketBeat recorded 17 mentions for IO Biotech and 2 mentions for Anixa Biosciences. IO Biotech's average media sentiment score of 1.27 beat Anixa Biosciences' score of 1.02 indicating that Anixa Biosciences is being referred to more favorably in the news media.
IO Biotech has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
IO Biotech presently has a consensus target price of $9.67, indicating a potential upside of 600.48%. Anixa Biosciences has a consensus target price of $12.00, indicating a potential upside of 321.05%. Given Anixa Biosciences' higher possible upside, equities research analysts clearly believe IO Biotech is more favorable than Anixa Biosciences.
Summary
Anixa Biosciences beats IO Biotech on 9 of the 15 factors compared between the two stocks.
Get Anixa Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anixa Biosciences Competitors List
Related Companies and Tools
